Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus

References

• Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7:812–821.
   PubMed Web of Science ®Google Scholar
• Quelle DE, Ashmun RA, Shurtleff SA, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993;7:1559–1571.
   PubMed Web of Science ®Google Scholar
• Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994;145:86–96.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Saito H, Kitano K, et al. Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32). Acta Haematol 1995;94:199–203.
   PubMed Web of Science ®Google Scholar
• Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994;84:2726–2732.
   PubMed Web of Science ®Google Scholar
• Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637–640.
   Google Scholar
• Troussard X, Avet-Loiseau H, Macro M, et al. Cyclin D1 expression in patients with multiple myeloma. Hematol J 2000;1:181–185.
   PubMedGoogle Scholar
• de Boer CJ, Kluin-Nelemans JC, Dreef E, et al. Involvement of the CCND1 gene in hairy cell leukemia. Ann Oncol 1996;7:251–256.
   PubMed Web of Science ®Google Scholar
• Ajchenbaum F, Ando K, DeCaprio JA, Griffin JD. Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem 1993;268:4113–4119.
   PubMed Web of Science ®Google Scholar
• Specht K, Kremer M, Muller U, et al. Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res 2002;8:2902–2911.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. LyonIARC Press2008.
   Google Scholar
• Teruya-Feldstein J, Gopalan A, Moskowitz CH. CD5 negative, cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen. Appl Immunohistochem Mol Morphol 2009;17:255–258.
   PubMedGoogle Scholar
• Rodriguez-Justo M, Huang Y, Ye H, et al. Cyclin D1-positive diffuse large B-cell lymphoma. Histopathology 2008;52:900–903.
   PubMed Web of Science ®Google Scholar
• Ehinger M, Linderoth J, Christensson B, Sander B, Cavallin-Stahl E. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. Am J Clin Pathol 2008;129:630–638.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Pittaluga S, Miething C, et al. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma. Blood 2006;108:2029–2036.
   PubMed Web of Science ®Google Scholar
• Specht K, Haralambieva E, Bink K, et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004;104:1120–1126.
   PubMed Web of Science ®Google Scholar
• Metcalf RA, Zhao S, Anderson MW, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol 2010;23:420–433.
   PubMed Web of Science ®Google Scholar
• Liu H, Wang J, Epner EM. Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 2004;104:2505–2513.
   PubMed Web of Science ®Google Scholar
• Camacho FI, Garcia JF, Cigudosa JC, et al. Aberrant Bcl6 protein expression in mantle cell lymphoma. Am J Surg Pathol 2004;28:1051–1056.
   PubMed Web of Science ®Google Scholar
• Gualco G, Weiss LM, Harrington WJ Jr, Bacchi CE. BCL6, MUM1, and CD10 expression in mantle cell lymphoma. Appl Immunohistochem Mol Morphol 2010;18:103–108.
   PubMedGoogle Scholar
• Liao DJ, Thakur A, Wu J, Biliran H, Sarkar FH. Perspectives on c-Myc, cyclin D1, and their interaction in cancer formation, progression, and response to chemotherapy. Crit Rev Oncog 2007;13:93–158.
   PubMedGoogle Scholar
• Baitei EY, Zou M, Al-Mohanna F, et al. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol 2009;217:707–715.
   PubMed Web of Science ®Google Scholar
• Intini D, Agnelli L, Ciceri G, et al. Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma. Hematol Oncol 2007;25:6–10.
   PubMed Web of Science ®Google Scholar
• O'Malley DP, Vance GH, Orazi A. Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall. Arch Pathol Lab Med 2005;129:92–95.
   PubMed Web of Science ®Google Scholar